We last looked at Pfizer (PFE) back on March 8 and wrote that "PFE may continue to hold around $34 and that's okay but the quantitative downgrade to hold and a Point and Figure target of $30 tells us to be careful as we could see a retest of the June low in the weeks ahead. It may not happen but luck favors the prepared."
More from Investing
Here's how I deal with my personal accounts in times of turmoil.
Here's my approach and how it fits into the current action.
The entertainment giant got rained on after Netflix's sour outlook, but parks and more should bring back the smiles for investors.
Interesting that I've not seen a single sell-side analyst upgrade, downgrade or reiterate anything. No changes made to price targets either.